New Cloud Medical, a Beijing-based medtech company specializing in chronic pain solutions, has announced the completion of its B+ financing round. The round was led by Dalton Venture, with participation from Taizhou Angel Fund and Qianfeng Investment. Funds will be directed toward clinical trials, regulatory submissions, and international expansion.

Chronic Pain: An Underestimated Global Challenge

• More than 20% of adults worldwide suffer from chronic pain (WHO).

• In China alone, patient numbers exceed 300 million, with over 30% aged 20–40.

• Standard pharmacological treatments often fail—neuropathic pain medications show efficacy in less than 50% of cases.

• Traditional surgical options are limited by cost, risk, and long recovery times.

This combination of unmet clinical need and rising patient awareness is driving demand for reversible, low-risk, and intelligent device-based therapies.

Technology Highlights

NewStim®: AI-Driven Closed-Loop Rechargeable Spinal Cord Stimulation (SCS)

• First domestically developed AI closed-loop rechargeable SCS system.

• Integrates ECAP (Evoked Compound Action Potential) real-time monitoring with AI adaptive algorithms.

• Automatically adjusts stimulation parameters in response to posture or neural signal changes.

• Collects over 4 million data points daily, enabling self-learning, remote updates, and individualized patient models.

• Supported under Beijing’s “AI + Healthcare” initiative; moving toward clinical trials.

NewMild®: Minimally Invasive PILD System

• First disposable device in China for percutaneous image-guided lumbar decompression (PILD).

• Enables precise ligamentum flavum decompression under X-ray guidance.

• Key benefits: single-use, precise targeting, minimal trauma, faster recovery.

• Especially suitable for elderly patients and lower-tier hospitals.

• Preparing for initial clinical studies in tertiary hospitals.

Existing Portfolio & Pipeline

Beyond these flagship products, New Cloud Medical has built a multi-layered portfolio covering non-invasive, minimally invasive, and implantable solutions. Its “Smart Cloud Patch,” a wearable designed for mild muscle pain and rehabilitation, has already reached the market. The NewMild® device targets lumbar spinal stenosis, while NewStim® focuses on drug-resistant neuropathic pain through closed-loop neurostimulation and remote management. This progressive portfolio structure allows the company to provide tailored therapeutic options based on disease type, patient condition, and treatment stage, while enhancing compatibility with hospital workflows and reimbursement systems.

Integrated R&D and Clinical Model

New Cloud Medical operates under a research–industry–clinic–application model:

• Industry: Manufacturing capacity for active implantable devices.

• Research: Joint development with Beijing University of Chemical Technology (materials, liquid electrodes).

• Clinical: Trials with leading hospitals such as China-Japan Friendship Hospital.

• Application: Real-world patient feedback loops for continuous product iteration.

Financing Priorities

With the completion of this B+ round, New Cloud Medical will advance regulatory approvals for NewStim® and NewMild®, while also initiating international clinical trials, including in the United States, to pursue FDA clearance. Investment will also strengthen its AI algorithm and material science capabilities, enabling further iterations of its closed-loop systems. The company is building physician- and patient-focused education platforms to increase adoption of new pain treatment technologies and is expanding indications into areas such as peripheral nerve stimulation, migraine, and cancer pain.

Outlook

With rising demand for smarter, minimally invasive pain solutions, New Cloud Medical is positioning itself as a challenger to established multinational players in the neurostimulation field. The next 2–3 years will be pivotal as the company scales its AI-enabled closed-loop SCS and builds an integrated product ecosystem for global pain management.

Sep 12, 2025, MedChina